Finally, erythroferrone was linked to both all-cause mortality and cardiovascular mortality.<h4>Conclusions</h4>Erythroferrone in CKD patients associated with the reticulocyte count and ESA dose and was inversely correlated with the hepcidin-to-ferritin ratio and TSAT, while its relationship with CKD stage may reflect ESA therapy. This evidence concerns the gene HAMP and chronic kidney disease.